These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 38813944)
1. Promising therapies for adults with symptomatic obstructive hypertrophic cardiomyopathy: 2023 and beyond. Gaballa A; Jadam S; Desai MY Expert Opin Pharmacother; 2024 May; 25(7):915-924. PubMed ID: 38813944 [TBL] [Abstract][Full Text] [Related]
2. An evaluation of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults. Dong T; Nissen S; Ospina S; Desai MY Expert Rev Cardiovasc Ther; 2023 Jan; 21(1):5-13. PubMed ID: 36522857 [TBL] [Abstract][Full Text] [Related]
3. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Olivotto I; Oreziak A; Barriales-Villa R; Abraham TP; Masri A; Garcia-Pavia P; Saberi S; Lakdawala NK; Wheeler MT; Owens A; Kubanek M; Wojakowski W; Jensen MK; Gimeno-Blanes J; Afshar K; Myers J; Hegde SM; Solomon SD; Sehnert AJ; Zhang D; Li W; Bhattacharya M; Edelberg JM; Waldman CB; Lester SJ; Wang A; Ho CY; Jacoby D; Lancet; 2020 Sep; 396(10253):759-769. PubMed ID: 32871100 [TBL] [Abstract][Full Text] [Related]
4. Medical therapies for hypertrophic cardiomyopathy: Current state of the art. Desai MY; Owens A; Wang A Prog Cardiovasc Dis; 2023; 80():32-37. PubMed ID: 37619712 [TBL] [Abstract][Full Text] [Related]
5. Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy. Desai MY; Wolski K; Owens A; Naidu SS; Geske JB; Smedira NG; Schaff H; Lampl K; McErlean E; Sewell C; Zhang D; Edelberg JM; Sehnert AJ; Nissen SE Am Heart J; 2021 Sep; 239():80-89. PubMed ID: 34038706 [TBL] [Abstract][Full Text] [Related]
6. Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy. Ho CY; Olivotto I; Jacoby D; Lester SJ; Roe M; Wang A; Waldman CB; Zhang D; Sehnert AJ; Heitner SB Circ Heart Fail; 2020 Jun; 13(6):e006853. PubMed ID: 32498620 [TBL] [Abstract][Full Text] [Related]
7. Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy. Zampieri M; Argirò A; Marchi A; Berteotti M; Targetti M; Fornaro A; Tomberli A; Stefàno P; Marchionni N; Olivotto I Curr Cardiol Rep; 2021 Jun; 23(7):79. PubMed ID: 34081217 [TBL] [Abstract][Full Text] [Related]
8. Mavacamten: A Novel Agent for Hypertrophic Cardiomyopathy. Chase Cole J; Benvie SF; DeLosSantos M Clin Ther; 2024 Apr; 46(4):368-373. PubMed ID: 38508915 [TBL] [Abstract][Full Text] [Related]
9. Medical Treatment Strategies for Hypertrophic Cardiomyopathy. Hutt E; Desai MY Am J Cardiol; 2024 Feb; 212S():S33-S41. PubMed ID: 38368034 [TBL] [Abstract][Full Text] [Related]
10. Cardiac Myosin Inhibitors: Expanding the Horizon for Hypertrophic Cardiomyopathy Management. Sykuta A; Yoon CH; Baldwin S; Rine NI; Young M; Smith A Ann Pharmacother; 2024 Mar; 58(3):273-285. PubMed ID: 37329113 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy. Ho CY; Mealiffe ME; Bach RG; Bhattacharya M; Choudhury L; Edelberg JM; Hegde SM; Jacoby D; Lakdawala NK; Lester SJ; Ma Y; Marian AJ; Nagueh SF; Owens A; Rader F; Saberi S; Sehnert AJ; Sherrid MV; Solomon SD; Wang A; Wever-Pinzon O; Wong TC; Heitner SB J Am Coll Cardiol; 2020 Jun; 75(21):2649-2660. PubMed ID: 32466879 [TBL] [Abstract][Full Text] [Related]
12. Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy. Hegde SM; Lester SJ; Solomon SD; Michels M; Elliott PM; Nagueh SF; Choudhury L; Zemanek D; Zwas DR; Jacoby D; Wang A; Ho CY; Li W; Sehnert AJ; Olivotto I; Abraham TP J Am Coll Cardiol; 2021 Dec; 78(25):2518-2532. PubMed ID: 34915982 [TBL] [Abstract][Full Text] [Related]
13. Mavacamten: a novel small molecule modulator of β-cardiac myosin for treatment of hypertrophic cardiomyopathy. Tower-Rader A; Ramchand J; Nissen SE; Desai MY Expert Opin Investig Drugs; 2020 Nov; 29(11):1171-1178. PubMed ID: 32897741 [TBL] [Abstract][Full Text] [Related]
14. Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions. Dong T; Alencherry B; Ospina S; Desai MY Drug Des Devel Ther; 2023; 17():1097-1106. PubMed ID: 37064432 [TBL] [Abstract][Full Text] [Related]
15. The Revolution of Cardiac Myosin Inhibitors in Patients With Hypertrophic Cardiomyopathy. Haraf R; Habib H; Masri A Can J Cardiol; 2024 May; 40(5):800-819. PubMed ID: 38280487 [TBL] [Abstract][Full Text] [Related]
16. Projecting the Long-term Clinical Value of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy in the United States: An Assessment of Net Health Benefit. Desai N; Xie J; Wang Y; Sutton MB; Whang J; Fine JT; Garrison LP Clin Ther; 2022 Jan; 44(1):52-66.e2. PubMed ID: 34911641 [TBL] [Abstract][Full Text] [Related]
17. Current and emerging pharmacotherapy for the management of hypertrophic cardiomyopathy. Rosenzveig A; Garg N; Rao SJ; Kanwal AK; Kanwal A; Aronow WS; Martinez MW Expert Opin Pharmacother; 2023; 24(12):1349-1360. PubMed ID: 37272195 [TBL] [Abstract][Full Text] [Related]
18. Hypertrophic cardiomyopathy: investigational drugs inhibiting myosin and upcoming agents. Hajj Ali A; Mehra N; Desai MY Expert Opin Investig Drugs; 2023; 32(9):849-853. PubMed ID: 37787068 [TBL] [Abstract][Full Text] [Related]